Measuring antifactor xa activity to monitor low-molecular-weight heparin in obesity: A critical review

Canadian Journal of Hospital Pharmacy

Volumn 68, Issue 1, 2015, Pages 33-47

  Egan, Gregory ^a   Ensom, Mary H H ^b  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Anti Xa; Antifactor Xa; Low molecular weight heparin; Therapeutic drug monitoring

Indexed keywords

BLOOD CLOTTING FACTOR 10A; LOW MOLECULAR WEIGHT HEPARIN;

ACUTE CORONARY SYNDROME; ALGORITHM; BARIATRIC SURGERY; BLEEDING; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; DRUG MONITORING; GENERAL SURGERY; HUMAN; MEDICATION COMPLIANCE; OBESITY; ORTHOPEDIC SURGERY; PATIENT COMPLIANCE; PHARMACOKINETIC PARAMETERS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

EID: 84939788404     PISSN: 00084123     EISSN: 19202903     Source Type: Journal    
DOI: 10.4212/cjhp.v68i1.1423     Document Type: Review

References (82)

1. Jorpes E. The chemistry of heparin. Am J Physiol. 1935;47:1817-30.
2. Hirsh J, Levine MN. Low molecular weight heparin. Blood. 1992;79(1):1-17.
3. Garcia DA, Baglin T P, Weitz JI, Samama MM; American College of Chest Physicians. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e24S-e43S.
4. Hoppensteadt D, Walenga JM, Fareed J, Bick RL. Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation. Hematol Oncol Clin North Am. 2003;17(1):313-41.
5. Quader MA, Stump LS, Sumpio BE. Low molecular weight heparins: current use and indications. J Am Coll Surg. 1998;187(6):641-58.
6. Krishnaswamy A, Lincoff M, Cannon C P. The use and limitations of unfractionated heparin. Crit Pathw Cardiol. 2010;9(1):35-40.
7. Linhardt RJ, Gunay NS. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost. 1999;25 Suppl 3:5-16.
8. Duplaga BA, Rivers C W, Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy. 2001; 21(2):218-34.
9. Erkens PMG, Prins MH. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboem-bolism. Cochrane Database Syst Rev. 2010;(9):CD001100.
10. Dolovich LR, Ginsberg JS, Doubets JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med. 2000;160(2):181-8.
11. Hull RD, Raskob GE, Pinea G F, Green D, Trowbridge AA, Elliott CG, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1992;326(15):975-82.
12. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med. 1999;341(11):793-800.
13. Pedersen PC, Ostergaard PB, Hedner U, Bergqvist D, Mätzsch T. Pharma-cokinetics of a low molecular weight heparin, logiparin, after intravenous and subcutaneous administration to healthy volunteers. Thromb Res. 1991;61(5-6):477-87.
14. Andrassy K, Eschenfelder V. Are the pharmacokinetic parameters of low molecular weight heparins predictive of their clinical efficacy? Thromb Res. 1996;81(2 Suppl):S29-38.
15. Andrassy K, Eschenfelder V, Koderisch J, Weber E. Pharmacokinetics of Clivarin a new low molecular weight heparin in healthy volunteers. Thromb Res. 1994;73(2):95-108.
16. Walenga JM, Hoppensteadt D, Fareed J. Laboratory monitoring of the clinical effects of low molecular weight heparins. Thromb Res Suppl. 1991; 14:49-62.
17. Lovenox (enoxaparin sodium injection) for subcutaneous and intravenous use [product monograph]. Bridgewater (NJ): Sanofi-Aventis U.S. LLC; 2013 [cited 2014 Jul 29]. Available from: www.accessdata.fda.gov/drugsatfda-docs/label/2013/020164s100lbl.pdf
18. Product monograph Fragmin® dalteparin sodium injection. Kirkland (QC): Pfizer Canada Inc; [revised 2014; cited 2015 Feb 2]. Available from: www. pfizer.ca/en/our-products/products/monograph/151
19. Product monograph Innohep® tinzaparin sodium sterile solution for SC injection. Thornhill (ON): LEO Pharma Inc; [revised 2010; cited 2015 Feb 3]. Available from: www.leo-pharma.ca/Files/Filer/LEO-local-downloads/LEO-Pharma.ca/innohep%20PM%20(3.0)%203-FEB-2011.pdf
20. Kandrotas RJ. Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 1992;22(5):359-74.
21. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the phar-macokinetics of drugs in humans. Clin Pharmacokinet. 2010;49(2):71-87.
22. Freeman AL, Pendleton RC, Rondina MT. Prevention of venous throm-boembolism in obesity. Expert Rev Cardiovasc Ther. 2010;8(12):1711-21.
23. George-Phillips KL, Bungard TJ. Use of low-molecular-weight heparin to bridge therapy in obese patients and in patients with renal dysfunction. Phar-macotherapy. 2006;26(10):1479-90.
24. Nutescu EA, Spinler SA, Wittkowsky A, Dager WE. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Phar-macother. 2009;43(6):1064-83.
25. Ensom MHH, Davis GA, Cropp CD, Ensom RJ. Clinical pharmacokinetics in the 21st century: does the evidence support definitive outcomes? Clin Pharmacokinet. 1998;34(4):265-79.
26. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):529-55.
27. Gaber TAZK. Guidelines for prevention of venous thromboembolism in immobile patients secondary to neurological impairment. Disabil Rehabil. 2007;29(19):1544-9.
28. Geerts WH, Jay RM, Code KI, Chen E, Szalai J P, Saibil EA, et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med. 1996;335(1):701-7.
29. Slavik RS, Chan E, Gorman SK, de Lemos J, Chittock D, Simons RK, et al. Dalteparin versus enoxaparin for venous thromboembolism prophylaxis in acute spinal cord injury and major orthopedic trauma patients: 'DETECT' trial. J Trauma. 2007;62(5):1075-81.
30. Spinal Cord Injury Thromboprophylaxis Investigators. Prevention of venous thromboembolism in the rehabilitation phase after spinal cord injury: prophylaxis with low-dose heparin or enoxaparin. J Trauma. 2003;54(6):1111-5.
31. Cohen M, Demers C, Gurfinkel E P, Turpie AG, Fromell GJ, Goodman S, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997;337(7):447-52.
32. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, et al; SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292(1):45-54.
33. Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-53.
34. Kitchen S. Problems in laboratory monitoring of heparin dosage. Br J Haematol. 2000;111(2):397-406.
35. Vandiver JW, Vondracek TG. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Pharmacotherapy. 2012;32(6):546-58.
36. Gehrie E, Laposata M. Test of the month: the chromogenic antifactor Xa assay. Am J Hematol. 2012;87(2):194-6.
37. Harris L F, Castro-López V, Hammadi N, O'Donnell JS, Killard AJ. Development of a fluorescent anti-factor Xa assay to monitor unfractionated and low molecular weight heparins. Talanta. 2010;81(4-5):1725-30.
38. Ping'an P, Mingzhao Q. Comparison of anti-Xa factor assay and ACT for monitoring the anticoagulation effects of low-molecular weight heparins in elderly patients. Heart. 2011;97:A188.
39. Gray E, Hogwood J, Rigsby P. Collaborative study for value assignment of the 3rd international standard for low molecular weight heparin. Geneva (Switzerland): World Health Organization, Expert Committee on Biological Standardization; 2012 [cited 2014 Jul 30]. Available from: http://apps.who.int/iris/bitstream/10665/78048/1/WHO-BS-2012.2207-eng.pdf
40. Heparin chromogenix monograph series. Chromogenix; 2010 [cited 2014 Jul 30]. Available from: www.chromogenix.com/monographs/060%20-%20 Heparin.pdf
41. Kitchen S, Iampietro R, Woolley AM, Preston FE. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability. Thromb Haemost. 1999;82(4):1289-93.
42. Gosselin RC, King JH, Janatpour KA, Dager WE, Larkin EC, et al. Variability of plasma anti-Xa activities with different lots of enoxaparin. Ann Pharmacother. 2004;38(4):563-8.
43. Koller M, Schoch U, Buchmann P, Largiadèr F, von Felten A, Frick PG. Low molecular weight heparin (KABI 2165) as thromboprophylaxis in elective visceral surgery. A randomized, double-blind study versus unfractionated heparin. Thromb Haemost. 1986;56(3):243-6.
44. Levine MN, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M. The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thromobosis after hip replacement. Thromb Haemost. 1989;62(3):940-4.
45. Turpie AGG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, et al. A randomized controlled trial of low-molecular weight heparin (enoxaparin) to prevent deep-vein thromobosis in patients undergoing elective hip surgery. N Engl J Med. 1986;315(15):925-9.
46. Bergqvist D, Burmark US, Frisell J, Hallböök T, Lindblad B, Risberg B, et al. Low molecular weight heparin once daily compared with conventional low heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis. Br J Surg. 1986:73(3):204-8.
47. Handeland G F, Abildgaard U, Holm HA, Arnesen KE. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol.1990;39(2):107-12.
48. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood. 1991;78(9):2337-43.
49. Bara L, Leizorowicz A, Picolet H, Samama M. Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in post-surgical patients treated with either logiparin (LMWH) or unfractionated heparin. Thromb Res. 1992;65(4-5):641-50.
50. Harenberg J, Huhle G, Piazolo L, Giese C, Heene DL. Long-term anticoag-ulation of outpatients with adverse events to oral anticoagulants using low-molecular-weight heparin. Semin Thromb Hemost. 1997;23(2):167-72.
51. Bara L, Planes A, Samama M. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and d-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery. Br J Haematol. 1999; 104(2):230-40.
52. Berges A, Laporte S, Epinat M, Zufferey P, Alamartine E, Tranchard B, et al. Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old. Br J Clin Pharmacol. 2007;64(4):428-38.
53. Green B, Duffull SB. Development of a dosing strategy for enoxaparin in obese patients. Br J Clin Pharmacol. 2003;56(1):96-103.
54. Kovacs MJ, Weir K, MacKinnon K, Keeney M, Brien WF, Cruickshank MK. Body weight does not predict anti-Xa levels after fixed dose prophylaxis with enoxaparin after orthopedic surgery. Thromb Res. 1998;91(3):137-42.
55. Prandoni P, Lensing AW, Büller HR, Carta M, Cogo A, Vigo M, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet. 1992; 339(8791):441-5.
56. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet. 2000;39(3):215-31.
57. Scholten DJ, Hoedema RM, Scholten SE. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg. 2002;12(1):19-24.
58. Imberti D, Legnani C, Baldini E, Cini M, Nicolini A, Guerra M, et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX Study). Thromb Res. 2009;124(6):667-71.
59. Borkgren-Okonek MJ, Hart RW, Pantano JE, Rantis PC Jr, Guske PJ, Kane JM Jr, et al. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity. Surg Obes Relat Dis. 2008;4(5):625-31.
60. Escalante-Tattersfield T, Tucker O, Fanjwaks P, Szomstein S, Rosenthal RJ. Incidence of deep vein thrombosis in morbidly obese patients undergoing laparoscopic Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2008;4(2):126-30.
61. Simoneau MD, Vachon A, Picard F. Effect of prophylactic dalteparin on anti-factor Xa levels in morbidly obese patients after bariatric surgery. Obes Surg. 2010;20(4):487-91.
62. Simone E P, Madan AK, Tichansky DS, Kuhl DA, Lee MD. Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery. Surg Endosc. 2008;22(11):2392-5.
63. Leizorovicz A, Bara L, Samama MM, Haugh MC. Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage. Haemostasis. 1993;23 Suppl 1:S89-98.
64. Kovacs MJ, Weir K, MacKinnon K, Keeney M, Brien WF, Cruickshank MK. Body weight does not predict anti-Xa level after fixed dose prophyalxis with enoxaparin after orthopedic surgery. Thromb Res. 1998;91(3):137-42.
65. Vavken P, Lunzer A, Grohs JG. A prospective cohort study on the effectiveness of 3500 IU versus 5000 IU bemiparin in the prophylaxis of postoperative thrombotic events in obese patients undergoing orthopedic surgery. Wien Klin Wochenschr. 2009;121(13-14):454-8.
66. Samama MM, Verhille C, Carchy L. Relation between weight, obesity, and frequency of deep vein thrombosis after enoxaparin in orthopedic surgery. Thromb Haemost. 1995;73:977-86.
67. Kucher N, Leizorovicz A, Vaitkus P T, Cohen AT, Turpie AG, Olsson CG, et al. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med. 2005;165(3):341-5.
68. Jiménez D, Díaz G, Iglesias A, César J, Garcia-Avello A, Martí D, et al. [Anti-factor Xa activity of enoxaparin for thromboprophylaxis in nonsurgical patients is dependent on body mass]. Spanish. Arch Bronconeumol. 2008; 44(12):660-3.
69. Rondina MT, Wheeler M, Rodgers GM, Draper L, Pendleton RC. Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-ill patients. Thromb Res. 2010;125(3):220-3.
70. Freeman A, Horner T, Pendleton RC, Rondina MT. Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity. Am J Hematol. 2012;87(7):740-3.
71. Wilson JA, Wilbur K, Burton E, Anderson DR. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism. Haemostasis. 2001;31(1):42-8.
72. Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J. 2003;146(1):33-41.
73. Davidson BL, Büller HR, Decousus H, Gallus A, Gent M, Piovella F, et al. Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. J Thromb Haemost. 2007;5(6):1191-4.
74. Smith J, Canton EM. Weight-based administration of dalteparin in obese patients. Am J Health Syst Pharm. 2003;60(7):683-7. Erratum in: Am J Health Syst Pharm. 2003;60(13):1306.
75. Al-Yaseen E, Wells PS, Anderson J, Martin J, Kovacs MJ. The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients. J Thromb Haemost. 2005;3(1):100-2.
76. Bazinet A, Almanric K, Brunet C, Turcotte I, Martineau J, Caron S, et al. Dosage of enoxaparin among obese and renal impairment patients. Thromb Res. 2005;116(1):41-50.
77. Barba R, Marco J, Martin-Alvarez H, Rondon P, Fernández-Capitan C, Garcia-Bragado F, et al. The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE). J Thromb Haemost. 2005;3(5):856-62.
78. Monte AA, Bodmer M, Schaeffer TH. Low-molecular-weight heparin overdose: management by observation. Ann Pharmacother.2010;44(11):1836-9.
79. Heizmann M, Baerlocher GM, Steinmann F, Horber F F, Wuillemin W. Anti-Xa activity in obese patients after double standard dose of nadroparin for prophylaxis. Thromb Res. 2002;106(4-5):179-81.
80. Yee JY, Duffull SB. The effect of body weight on dalteparin pharmacokinetics. A preliminary study. Eur J Clin Pharmacol. 2000;56(4):293-7.
81. Hainer JW, Barrett JS, Assaid CA, Fossler MJ, Cox DS, Leather T, et al. Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost. 2002;87(5):817-23.
82. Sanderink GI, Le Liboux A, Jariwala N, Harding N, Ozoux ML, Shukla U, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther. 2002;72(3):308-18.